ArticleFrontiers in microbiology2021
Molecular Epidemiology and Characteristics of CTX-M-55 Extended-Spectrum β-Lactamase-Producing
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 43 citations in OpenAlex.
- Role of extended-spectrum β-lactamase (ESBL) genes in the dissemination of β-lactam resistance within aquatic environments: mechanisms, persistence, and one health implications.World journal of microbiology & biotechnology · 2026Review
- Article
- Molecular and Microbiological Characteristics of UropathogenicAnnals of laboratory medicine · 2026Article
- Genomic Diversity and Extended-SpectrumInternational journal of microbiology · 2026Article
- Prospective Molecular and Phenotypic Characterization ofInfection and drug resistance · 2026Article
- High prevalence ofApplied and environmental microbiology · 2025Article
- Genetic characteristics and risk factors of extended-spectrum β-lactamase-producingMicrobiology spectrum · 2025Observational
- Multidrug Resistance, Biofilm-Forming Ability, and Molecular Characterization ofAntibiotics (Basel, Switzerland) · 2025Article
- Article
- Dissemination of Ceftriaxone-ResistantAntibiotics (Basel, Switzerland) · 2024Article
- Presence of phage-plasmids in multiple serovars ofMicrobial genomics · 2024Article
- Current epidemiologic features and health dynamics of ESBL-producingBiosafety and health · 2024Review
- Genome-Based Molecular Diversity of Extended-SpectrumTransboundary and emerging diseases · 2024Article
- Emergence of aInfection and drug resistance · 2024Article
- Multidrug-ResistantMicroorganisms · 2023Article
- Detection of extended-spectrum β-lactamase-producingVeterinary world · 2023Review
- Temporal dynamics of genetically heterogeneous extended-spectrum cephalosporin-resistantmSphere · 2023Article
- Genomic Insights into GlobalMicrobiology spectrum · 2023Article
- Comparative Genetic Characterization of CTX-M-ProducingMicroorganisms · 2023Article
- Exploring the epidemiology of mcr genes, genetic context and plasmids in Enterobacteriaceae originating from pigs and humans on farms in Thailand.The Journal of antimicrobial chemotherapy · 2023Article
Corrections and comments
- Erratum issued
Authors and funding
7 authors at 4 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In recent years, the CTX-M-55 extended-spectrum β-lactamase (ESBL)-positive rate has gradually increased in the clinic. To identify the molecular epidemiology and characteristics of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.